Optrascan v. Morphle Labs: Dismissed on Venue Grounds in Digital Pathology Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Optrascan, Inc. v. Morphle Labs, Inc. |
| Case Number | 1:23-cv-00733 |
| Court | U.S. District Court for the Western District of Texas |
| Duration | Jun 2023 – Apr 2024 10 months |
| Outcome | Defendant Win — Dismissed without Prejudice (Venue) |
| Patents at Issue | |
| Accused Products | HemoLens and MorphoLens 240 |
Case Overview
The Parties
⚖️ Plaintiff
Developer of whole slide imaging and digital pathology solutions, holding an IP portfolio directed at high-resolution microscopic scanning systems.
🛡️ Defendant
Digital pathology company offering AI-integrated imaging products, including the accused HemoLens and MorphoLens 240 whole slide scanners.
Patents at Issue
Two issued U.S. patents formed the basis of the infringement action, relating to core technologies underlying whole slide imaging systems in the rapidly expanding digital pathology market.
- • U.S. Patent No. 10,338,365 B2 — directed to optical scanning and imaging system architecture
- • U.S. Patent No. 10,586,376 B2 — directed to imaging and visualization methods applicable to digital pathology workflows
Developing digital pathology products?
Ensure your innovations don’t infringe active patents like these. Run an FTO check.
The Verdict & Legal Analysis
Outcome
The U.S. District Court for the Western District of Texas dismissed all of Optrascan’s infringement claims against Morphle Labs without prejudice. No damages were awarded, and no injunctive relief was granted or denied on the merits. This dismissal allows Optrascan to refile its claims in a court of proper venue.
Key Legal Issues
The dismissal rests entirely on **improper venue** under Federal Rule of Civil Procedure 12(b)(3). In patent cases, venue is governed by 28 U.S.C. § 1400(b), which requires that the defendant either be incorporated in the district or have committed acts of infringement and maintain a regular and established place of business there. Following the Supreme Court’s 2017 ruling in TC Heartland LLC v. Kraft Foods Group Brands LLC, patent venue rules tightened considerably, which Morphle Labs successfully leveraged in this case.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in the digital pathology market. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View active and related patents in digital pathology
- Analyze venue challenges in the Western District of Texas
- Understand the procedural vulnerabilities of patent cases
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Venue Dismissal Does Not Grant Safe Harbor
2 Active Patents
US 10,338,365 & 10,586,376
Filing Strategy
Crucial for digital pathology IP
✅ Key Takeaways
Venue compliance under 28 U.S.C. § 1400(b) is non-negotiable post-TC Heartland — confirm before filing.
Search related case law →Rule 12(b)(3) motions remain among the highest-value early defense strategies in patent cases.
Explore precedents →Dismissal without prejudice preserves plaintiff’s claims but erodes tactical advantage and incurs duplicative costs.
Understand litigation strategy →Frequently Asked Questions
The case involved U.S. Patent No. 10,338,365 B2 and U.S. Patent No. 10,586,376 B2, both covering digital pathology imaging technologies. The accused products were the HemoLens and MorphoLens 240.
The Western District of Texas dismissed the case without prejudice under Federal Rule of Civil Procedure 12(b)(3) for improper venue — not on the merits of infringement or patent validity.
Yes. A dismissal without prejudice allows Optrascan to refile in a court of proper venue. The underlying infringement dispute remains legally unresolved.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER Case Locator – Case 1:23-cv-00733
- USPTO Patent Full-Text Database
- Cornell Legal Information Institute — 28 U.S.C. § 1400(b)
- TC Heartland LLC v. Kraft Foods Group Brands LLC, 581 U.S. 258 (2017)
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.